Speakers

• 

  Georgios Papazisis Professor of Basic and Clinical Pharmacology at the Department of Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki
  

  Georgios Papazisis

  Professor of Basic and Clinical Pharmacology at the Department of Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki

  Dr. Georgios Papazisis is a Full Professor of Basic and Clinical Pharmacology at the Department of Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Greece.
  He is a specialized Psychiatrist and has also obtained the Greek Medical board certification of the medical sub-specialty of Clinical Pharmacology.
  Currently, he is the Medical Director of the Clinical Research Unit of the School of Medicine, at the Papageorgiou Hospital in Thessaloniki, coordinating early phase clinical trials.
  Dr Papazisis currently serves as the:
  · Co-chair of the newly formed Special Interest Group (SIG) on ‘Pragmatic trials’ of the European Network of Centres for Pharmacoepidemiology & Pharmacovigilance (ENCePP) coordinated by the European Medicines Agency (EMA).
  · Administrator for the Aristotle University Organization of the NIH US National Library of Medicine clinical trial registry ClinicalTrials.gov.
  · Pharmacovigilance referent person for the Greek National Hub in the conect4children (c4c) project
  · Chair of the Committee for Bioethics and Medical Ethics of the School of Medicine.
  · Principal Investigator for the Phase III study: An Efficacy and Safety, Phase III, Multi-center, Double-Blind, Randomized Controlled Study Comparing 2 Active Doses of CYB003 and Placebo in Eligible Participants with Major Depressive Disorder (EMBRACE)
  Dr Papazisis is member of the management Board of the Greek National Regulatory Organization for Medicines (ΕΟΦ) and also the Greek delegate of the UEMS (Union Européenne des Médecins Spécialistes) section of Pharmacology, UEMS member of the i. newly established Federation for Medical Ethics and also the ii. thematic Federation for Equality, Diversity & Inclusivity.

• 

  Achilleas Gravanis CEO ReNeuroCell Thearapeutics
  

  Achilleas Gravanis

  CEO ReNeuroCell Thearapeutics

  Achilleas Gravanis, former Professor of Pharmacology, School of Medicine, University of Crete, and Researcher at the Institute of Molecular Biology & Biotechnology (IMBB), FORTH (Foundation for Research and Technology – Hellas). He is an Adjunct Professor of Pharmacology at the School of Pharmacy, Northeastern University, Boston.

  He has served as a member of the European Commission’s Biomedical Research Programme Committee, a member of the Council of the Hellenic Authority for Higher Education Quality Assurance (HAHE), and President of the Sectoral Scientific Council of Life Sciences of the National Council for Research & Technology (NCRT).

  He has also served as a member of the Scientific Council of the Hellenic Foundation for Research & Innovation (HFRI), responsible for Life Sciences, and as an Associate Principal Investigator at Emulate, a spin-off of the Wyss Institute/Harvard Medical School.

  He is a co-founder of the biotechnology spin-off companies Bionature SA and ReNeuroCell Therapeutics, which are engaged in the development of new therapies for neurodegenerative diseases and brain injury.